Sarepta Retained Earnings from 2010 to 2024

SRPT Stock

USD 133.34 4.60 3.33%

Sarepta Therapeutics Retained Earnings yearly trend continues to be comparatively stable with very little volatility. Retained Earnings are likely to outpace its year average in 2024. Retained Earnings is the cumulative amount of net income that Sarepta Therapeutics retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

1996-12-31

Previous Quarter

-4.4 B

Current Value

-4.4 B

Quarterly Volatility

1.3 B

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Sarepta Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sarepta Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 61.8 M, Interest Expense of 23.1 M or Selling General Administrative of 475.9 M, as well as many indicators such as Price To Sales Ratio of 6.81, Dividend Yield of 0.0 or PTB Ratio of 6.7. Sarepta financial statements analysis is a perfect complement when working with Sarepta Therapeutics Valuation or Volatility modules.

Check out the analysis of Sarepta Therapeutics Correlation against competitors.

For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.

Latest Sarepta Therapeutics' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Sarepta Therapeutics over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Sarepta Therapeutics' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sarepta Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (4.45 B)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Sarepta Retained Earnings Regression Statistics

	Arithmetic Mean	(1,850,954,290)
	Coefficient Of Variation	(82.12)
	Mean Deviation	1,309,800,481
	Median	(1,217,008,000)
	Standard Deviation	1,520,061,126
	Sample Variance	2310585.8T
	Range	4.4B
	R-Value	(0.97)
	Mean Square Error	159433.1T
	R-Squared	0.94
	Slope	(328,826,762)
	Total Sum of Squares	32348201.6T

Sarepta Retained Earnings History

	2024	-4.2 B
	2023	-4.4 B
	2022	-3.9 B
	2021	-3.2 B
	2020	-2.8 B
	2019	-2.3 B
	2018	-1.6 B

Other Fundumenentals of Sarepta Therapeutics

Retained Earnings Total Equity

Sarepta Therapeutics Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Property Plant Equipment	Net Receivables	Current Deferred Revenue	Long Term Debt	Short Term Debt	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Short Long Term Debt	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock
Total Assets		0.79	0.34	-0.97	0.9	0.75	0.98	1.0	0.78	-0.3	0.97	0.86	0.84	0.97	0.76	0.63	0.99	0.99	0.93	0.96	0.05	0.92	0.88
Total Stockholder Equity	0.79		0.11	-0.71	0.63	0.61	0.64	0.8	0.76	-0.38	0.69	0.57	0.42	0.67	0.73	0.93	0.76	0.81	0.81	0.65	0.37	0.56	0.56
Net Debt	0.34	0.11		-0.5	0.58	0.82	0.39	0.31	0.56	-0.01	0.53	0.69	0.1	0.39	-0.1	-0.19	0.4	0.41	0.36	0.35	-0.26	0.17	0.51
Retained Earnings	-0.97	-0.71	-0.5		-0.95	-0.81	-0.97	-0.96	-0.82	0.33	-0.99	-0.93	-0.78	-0.96	-0.66	-0.5	-0.97	-0.98	-0.9	-0.96	0.08	-0.87	-0.94
Accounts Payable	0.9	0.63	0.58	-0.95		0.81	0.91	0.88	0.87	-0.26	0.97	0.96	0.71	0.86	0.64	0.36	0.92	0.92	0.86	0.9	-0.19	0.82	0.91
Short Term Investments	0.75	0.61	0.82	-0.81	0.81		0.72	0.74	0.79	-0.24	0.82	0.85	0.44	0.74	0.35	0.35	0.76	0.79	0.73	0.68	0.05	0.54	0.71
Total Liab	0.98	0.64	0.39	-0.97	0.91	0.72		0.97	0.71	-0.24	0.97	0.88	0.9	0.98	0.7	0.48	0.98	0.95	0.89	0.97	-0.06	0.95	0.91
Total Current Assets	1.0	0.8	0.31	-0.96	0.88	0.74	0.97		0.76	-0.31	0.95	0.84	0.84	0.97	0.76	0.66	0.99	0.98	0.92	0.94	0.08	0.91	0.86
Intangible Assets	0.78	0.76	0.56	-0.82	0.87	0.79	0.71	0.76		-0.35	0.82	0.88	0.44	0.67	0.6	0.47	0.8	0.83	0.72	0.72	-0.18	0.6	0.78
Common Stock	-0.3	-0.38	-0.01	0.33	-0.26	-0.24	-0.24	-0.31	-0.35		-0.27	-0.19	-0.19	-0.25	-0.19	-0.36	-0.25	-0.33	-0.26	-0.22	-0.08	-0.2	-0.19
Property Plant Equipment	0.97	0.69	0.53	-0.99	0.97	0.82	0.97	0.95	0.82	-0.27		0.94	0.79	0.95	0.67	0.47	0.97	0.98	0.92	0.96	-0.07	0.88	0.93
Net Receivables	0.86	0.57	0.69	-0.93	0.96	0.85	0.88	0.84	0.88	-0.19	0.94		0.65	0.84	0.56	0.27	0.9	0.89	0.8	0.88	-0.26	0.77	0.94
Current Deferred Revenue	0.84	0.42	0.1	-0.78	0.71	0.44	0.9	0.84	0.44	-0.19	0.79	0.65		0.85	0.73	0.35	0.81	0.76	0.68	0.86	-0.05	0.97	0.74
Long Term Debt	0.97	0.67	0.39	-0.96	0.86	0.74	0.98	0.97	0.67	-0.25	0.95	0.84	0.85		0.64	0.54	0.97	0.95	0.89	0.94	0.0	0.9	0.88
Short Term Debt	0.76	0.73	-0.1	-0.66	0.64	0.35	0.7	0.76	0.6	-0.19	0.67	0.56	0.73	0.64		0.65	0.73	0.72	0.73	0.77	0.26	0.82	0.61
Net Tangible Assets	0.63	0.93	-0.19	-0.5	0.36	0.35	0.48	0.66	0.47	-0.36	0.47	0.27	0.35	0.54	0.65		0.58	0.63	0.68	0.47	0.57	0.43	0.3
Long Term Debt Total	0.99	0.76	0.4	-0.97	0.92	0.76	0.98	0.99	0.8	-0.25	0.97	0.9	0.81	0.97	0.73	0.58		0.98	0.92	0.96	-0.04	0.9	0.91
Capital Surpluse	0.99	0.81	0.41	-0.98	0.92	0.79	0.95	0.98	0.83	-0.33	0.98	0.89	0.76	0.95	0.72	0.63	0.98		0.94	0.94	0.03	0.86	0.89
Short Long Term Debt	0.93	0.81	0.36	-0.9	0.86	0.73	0.89	0.92	0.72	-0.26	0.92	0.8	0.68	0.89	0.73	0.68	0.92	0.94		0.9	0.26	0.8	0.81
Net Invested Capital	0.96	0.65	0.35	-0.96	0.9	0.68	0.97	0.94	0.72	-0.22	0.96	0.88	0.86	0.94	0.77	0.47	0.96	0.94	0.9		-0.03	0.95	0.95
Long Term Investments	0.05	0.37	-0.26	0.08	-0.19	0.05	-0.06	0.08	-0.18	-0.08	-0.07	-0.26	-0.05	0.0	0.26	0.57	-0.04	0.03	0.26	-0.03		-0.05	-0.26
Net Working Capital	0.92	0.56	0.17	-0.87	0.82	0.54	0.95	0.91	0.6	-0.2	0.88	0.77	0.97	0.9	0.82	0.43	0.9	0.86	0.8	0.95	-0.05		0.85
Capital Stock	0.88	0.56	0.51	-0.94	0.91	0.71	0.91	0.86	0.78	-0.19	0.93	0.94	0.74	0.88	0.61	0.3	0.91	0.89	0.81	0.95	-0.26	0.85

Click cells to compare fundamentals

About Sarepta Therapeutics Financial Statements

Sarepta Therapeutics shareholders use historical fundamental indicators, such as Retained Earnings, to determine how well the company is positioned to perform in the future. Although Sarepta Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Sarepta Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Sarepta Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Retained Earnings	-4.4 B	-4.2 B
Retained Earnings Total Equity	-2.9 B	-2.7 B

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Sarepta Stock Analysis

When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC